Ascendis Pharma A/S
ASNDNASDAQHealthcare● Active
$210.45
$-8.39(-3.83%)
Market Cap$13.0B
P/E Ratio—
52W High$250.74
52W Low$160.86
Ascendis Pharma A/S (ASND) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
ASND · earnings · updated Jun 8, 2026
Latest Earnings
Q2 FY2026Report Date: May 7, 2026EPS Actual
$0.32
Est. $0.19 · +70.6%
Revenue
$0.28B
Est. $0.31B · -7.8%
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 7, 2026
After Market Close
▲ Beat EPS▼ Miss Revenue✓ 1-Quarter EPS Beat Streak
ASND reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
85
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
$0.37
Rev. $0.36B
Days Away85
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.$0.37
Rev. Est.$0.36B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 6, 2026 | $1.13 | — | — | — | $0.45B | — |
| ▲ Q2 FY2026 | May 7, 2026 | $0.19 | $0.32 | +70.6% | $0.28B | $0.31B | -7.8% |
| ▼ Q1 FY2026 | Feb 11, 2026 | -$0.06 | -$0.64 | -966.7% | $0.34B | $0.29B | +18.0% |
| ▼ Q4 FY2025 | Nov 12, 2025 | -$0.41 | -$1.17 | -185.4% | $0.25B | $0.30B | -17.3% |
| ▲ Q3 FY2025 | Aug 7, 2025 | -$1.42 | -$0.93 | +34.5% | $0.19B | $0.23B | -20.2% |
| ▼ Q2 FY2025 | May 1, 2025 | -$1.56 | -$1.66 | -6.4% | $0.11B | $0.15B | -27.9% |
| ▲ Q1 FY2025 | Feb 12, 2025 | -$1.20 | -$0.68 | +43.3% | $0.18B | $0.13B | +43.6% |
| ▲ Q4 FY2024 | Nov 14, 2024 | -$1.83 | -$1.81 | +1.1% | $0.06B | $0.07B | -14.4% |
Q3 FY2026
Aug 6, 2026
EPS Actual
—
EPS Est.
$1.13
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 7, 2026Beat
EPS Actual
$0.32
EPS Est.
$0.19
EPS Surpr.
+70.6%
Revenue
$0.28B
Q1 FY2026
Feb 11, 2026Miss
EPS Actual
-$0.64
EPS Est.
-$0.06
EPS Surpr.
-966.7%
Revenue
$0.34B
Q4 FY2025
Nov 12, 2025Miss
EPS Actual
-$1.17
EPS Est.
-$0.41
EPS Surpr.
-185.4%
Revenue
$0.25B
Q3 FY2025
Aug 7, 2025Beat
EPS Actual
-$0.93
EPS Est.
-$1.42
EPS Surpr.
+34.5%
Revenue
$0.19B
Q2 FY2025
May 1, 2025Miss
EPS Actual
-$1.66
EPS Est.
-$1.56
EPS Surpr.
-6.4%
Revenue
$0.11B
Q1 FY2025
Feb 12, 2025Beat
EPS Actual
-$0.68
EPS Est.
-$1.20
EPS Surpr.
+43.3%
Revenue
$0.18B
Q4 FY2024
Nov 14, 2024Beat
EPS Actual
-$1.81
EPS Est.
-$1.83
EPS Surpr.
+1.1%
Revenue
$0.06B
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $3.08 | $3.43 | $4.27 | 2 |
| Q3 FY2027 | $2.60 | $2.90 | $3.60 | 2 |
| Q2 FY2027 | $2.15 | $2.40 | $2.98 | 2 |
| Q1 FY2027 | $1.74 | $1.93 | $2.40 | 2 |
| Q4 FY2026 | $1.08 | $1.20 | $1.49 | 4 |
| Q3 FY2026 | $0.56 | $1.15 | $1.43 | 6 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $0.5B | $0.6B | $0.7B | 5 |
| Q3 FY2027 | $0.5B | $0.5B | $0.6B | 5 |
| Q2 FY2027 | $0.5B | $0.5B | $0.6B | 5 |
| Q1 FY2027 | $0.4B | $0.4B | $0.5B | 5 |
| Q4 FY2026 | $0.4B | $0.4B | $0.5B | 5 |
| Q3 FY2026 | $0.3B | $0.4B | $0.4B | 10 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▲ Q2 FY2026 | May 7, 2026 | +70.6% | $235.90 | $246.14 | +4.34% |
| ▼ Q1 FY2026 | Feb 11, 2026 | -966.7% | $224.19 | $221.49 | -1.20% |
| ▼ Q4 FY2025 | Nov 12, 2025 | -185.4% | $201.16 | $199.22 | -0.96% |
| ▲ Q3 FY2025 | Aug 7, 2025 | +34.5% | $182.60 | $190.35 | +4.24% |
| ▼ Q2 FY2025 | May 1, 2025 | -6.4% | $170.44 | $167.47 | -1.74% |
| ▲ Q1 FY2025 | Feb 12, 2025 | +43.3% | $119.51 | $126.14 | +5.55% |
| ▲ Q4 FY2024 | Nov 14, 2024 | +1.1% | $126.03 | $124.28 | -1.39% |
| ▼ Q3 FY2024 | Sep 3, 2024 | -33.1% | No price data | $134.68 | — |
Q2 FY2026+4.34%
Report Date
May 7, 2026
EPS Beat/Miss
+70.6%
Price Before
$235.90
Price After
$246.14
Q1 FY2026-1.20%
Report Date
Feb 11, 2026
EPS Beat/Miss
-966.7%
Price Before
$224.19
Price After
$221.49
Q4 FY2025-0.96%
Report Date
Nov 12, 2025
EPS Beat/Miss
-185.4%
Price Before
$201.16
Price After
$199.22
Q3 FY2025+4.24%
Report Date
Aug 7, 2025
EPS Beat/Miss
+34.5%
Price Before
$182.60
Price After
$190.35
Q2 FY2025-1.74%
Report Date
May 1, 2025
EPS Beat/Miss
-6.4%
Price Before
$170.44
Price After
$167.47
Q1 FY2025+5.55%
Report Date
Feb 12, 2025
EPS Beat/Miss
+43.3%
Price Before
$119.51
Price After
$126.14
Q4 FY2024-1.39%
Report Date
Nov 14, 2024
EPS Beat/Miss
+1.1%
Price Before
$126.03
Price After
$124.28
Q3 FY2024—
Report Date
Sep 3, 2024
EPS Beat/Miss
-33.1%
Price Before
—
Price After
$134.68
Avg Beat Reaction+3.18%
Avg Miss Reaction-1.30%
Beat Rate4 / 8 quarters
Largest Move+5.55% (Q1 FY2025)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: ASND ends December
Ascendis Pharma A/S (ASND) most recently reported earnings on May 7, 2026 for Q2 FY2026, posting EPS of $0.32 — beating the analyst consensus of $0.19 by +70.6%. The next ASND earnings date is expected around September 1, 2026.
Each quarter, investors track ASND earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. ASND revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
ASND's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
ASND earnings · 5 questionsAscendis Pharma A/S's next earnings report is expected around September 1, 2026. ASND typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; ASND historically reports after market close (AMC).
ASND earnings datewhen is ASND earningsASND next earnings datewhen does ASND report earningsASND earnings calendar
▸ Source: FMP · Ascendis Pharma A/S SEC filings · US GAAP · Ascendis Pharma A/S SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026